- Home
- SPOK vs SGHT Comparison
SPOK vs SGHT Comparison
Compare SPOK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- SGHT
- Stock Information
- Founded
- SPOK 2004
- SGHT 2011
- Country
- SPOK United States
- SGHT United States
- Employees
- SPOK N/A
- SGHT N/A
- Industry
- SPOK Telecommunications Equipment
- SGHT Medical Specialities
- Sector
- SPOK Telecommunications
- SGHT Health Care
- Exchange
- SPOK Nasdaq
- SGHT Nasdaq
- Market Cap
- SPOK 329.2M
- SGHT 304.4M
- IPO Year
- SPOK 1992
- SGHT 2021
- Fundamental
- Price
- SPOK $15.92
- SGHT $2.83
- Analyst Decision
- SPOK Hold
- SGHT Buy
- Analyst Count
- SPOK 1
- SGHT 7
- Target Price
- SPOK $15.00
- SGHT $5.10
- AVG Volume (30 Days)
- SPOK 98.5K
- SGHT 260.5K
- Earning Date
- SPOK 02-19-2025
- SGHT 03-06-2025
- Dividend Yield
- SPOK 7.86%
- SGHT N/A
- EPS Growth
- SPOK N/A
- SGHT N/A
- EPS
- SPOK 0.71
- SGHT N/A
- Revenue
- SPOK $137,714,000.00
- SGHT $79,543,000.00
- Revenue This Year
- SPOK $2.45
- SGHT $2.13
- Revenue Next Year
- SPOK $0.80
- SGHT $7.99
- P/E Ratio
- SPOK $22.41
- SGHT N/A
- Revenue Growth
- SPOK N/A
- SGHT N/A
- 52 Week Low
- SPOK $13.24
- SGHT $2.68
- 52 Week High
- SPOK $18.14
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- SPOK 47.46
- SGHT 22.86
- Support Level
- SPOK $15.32
- SGHT $3.46
- Resistance Level
- SPOK $16.25
- SGHT $3.34
- Average True Range (ATR)
- SPOK 0.30
- SGHT 0.16
- MACD
- SPOK 0.02
- SGHT -0.04
- Stochastic Oscillator
- SPOK 61.22
- SGHT 14.69
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.